［1］Natarajan H.Plasma imatinib trough level measurements is still appropriate to predict therapeutic responses in patients with chronic myeloid leukemia［J］.Leuk Lymphoma，2019：1-2.
［2］Park JH，Woo YM，Youm EM，et al.HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia［J］.Leukemia，2018.
［3］Hantel A，Larson RA.Imatinib is still recommended for frontline therapy for CML［J］.Blood Adv，2018，2(24)：3648-3652.
［4］Bhatia S，Diedrich D，Frieg B，et al.Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response［J］.Blood，2018，132(3)：307-320.
［5］Claudiani S，Apperley JF.The argument for using imatinib in CML［J］.Hematology Am Soc Hematol Educ Program，2018，2018(1)：161-167.
［6］Ellis M，Krashin E，Hamburger-Avnery O，et al.The anti-leukemic and lipid lowering effects of imatinib are not hindered by statins in CML：A retrospective clinical study and in vitro assessment of lipid-genes transcription［J］.Leuk Lymphoma，2017，58(5)：1172-1177.
［7］Mukhopadhyay A，Dasgupta S，Kanti RU，et al.Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy［J］.Ir J Med Sci，2015，184(1)：183-188.
［8］Pye SM，Cortes J，Ault P，et al.The effects of imatinib on pregnancy outcome［J］.Blood，2008，111(12)：5505-5508.
［9］Kobayashi K，Takebayashi C，Miyata S，et al.Successful delivery after planned discontinuation of imatinib in a patient with chronic myeloid leukemia［J］.Intern Med，2009，48(5)：369-371.
［10］Carlier P，Markarian M，Bernard N，et al.Pregnancy outcome among partners of male patients receiving imatinib，dasatinib or nilotinib in chronic myeloid leukemia：Reports collected by the French network pharmacovigilance centers［J］.Arch Gynecol Obstet，2017，295(2)：269-271.
［11］Moura AC，Delamain MT，Duarte G，et al.Management of chronic myeloid leukemia during pregnancy：A retrospective analysis at a single center［J］.Hematol Transfus Cell Ther，2019，41(2)：125-128.
［12］Burwick RM，Kuo K，Brewer D，et al.Maternal，Fetal，and neonatal imatinib levels with treatment of chronic myeloid leukemia in pregnancy［J］.Obstet Gynecol，2017，129(5)：831-834.
［13］Schultheis B，Nijmeijer BA，Yin H，et al.Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model［J］.Leuk Res，2012，36(3)：271-274.
［14］Cengiz SG，Ozkavukcu S，Seval M，et al.Gonadotoxic effects of nilotinib in chronic myeloid leukemia treatment dose in a mouse model［J］.Turk J Haematol，2017，34(2)：137-142.
［15］Seshadri T，Seymour JF，McArthur GA.Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome［J］.N Engl J Med，2004，351(20)：2134-2135.
［16］Nicolini FE，Alcazer V，Huguet F，et al.CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment［J］.Leuk Res，2016（48）：80-83.
［17］Wang SA，Hasserjian RP，Tam W，et al.Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia，not otherwise specified and reactive idiopathic hypereosinophilic syndrome［J］.Haematologica，2017，102(8)：1352-1360.
［18］Heim C，Minniear K，Dann CT.Imatinib has deleterious effects on differentiating spermatogonia while sparing spermatogonial stem cell self renewal［J］.Reprod Toxicol，2011，31(4)：454-463.
［19］Michailov Y，Lunenfeld E，Kapilushnik J，et al.Acute myeloid leukemia affects mouse sperm parameters，spontaneous acrosome reaction，and fertility capacity［J］.Int J Mol Sci，2019，20(1).